BIOSECURE Act Targets China but Fails to Address Fallout for US Biopharma

It’s time for Congress to step up and fund America’s supply chain independence from Chinese companies by bolstering our domestic manufacturing capabilities.
This week, the House of Representatives overwhelmingly passed the BIOSECURE Act by a bipartisan vote of 306 to 81, as Congress seeks to prohibit contracting with certain Chinese “companies of concern” to U.S. national security. Strong congressional support for the bill was not surprising given House Speaker Mike Johnson’s promise in July that he intended to have a “significant package of China-related legislation” signed into law by the end of this year.